Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Top High Potency APIs (HPAPI) Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global High Potency APIs (HPAPI) Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Innovative
1.3.3 Generic
1.4 Market Segment by Application
1.4.1 Global High Potency APIs (HPAPI) Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Oncology
1.4.3 Glaucoma
1.4.4 Hormonal Imbalance
1.4.5 Respiratory Disorders
1.4.6 Other
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global High Potency APIs (HPAPI) Revenue (2015-2026)
2.1.1 Global High Potency APIs (HPAPI) Revenue (2015-2026)
2.1.2 Global High Potency APIs (HPAPI) Sales (2015-2026)
2.2 High Potency APIs (HPAPI) Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global High Potency APIs (HPAPI) Sales by Regions (2015-2020)
2.2.2 Global High Potency APIs (HPAPI) Revenue by Regions (2015-2020)
2.3 Global Top High Potency APIs (HPAPI) Regions (Countries) Ranking by Market Size
2.4 High Potency APIs (HPAPI) Industry Trends
2.4.1 High Potency APIs (HPAPI) Market Top Trends
2.4.2 Market Drivers
2.4.3 High Potency APIs (HPAPI) Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key High Potency APIs (HPAPI) Players: Views for Future
3 Competitive Landscape by Manufacturers
3.1 Global Top High Potency APIs (HPAPI) Manufacturers by Sales (2015-2020)
3.1.1 Global High Potency APIs (HPAPI) Sales by Manufacturers (2015-2020)
3.1.2 Global High Potency APIs (HPAPI) Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by High Potency APIs (HPAPI) Sales in 2019
3.2 Global Top Manufacturers High Potency APIs (HPAPI) by Revenue
3.2.1 Global High Potency APIs (HPAPI) Revenue by Manufacturers (2015-2020)
3.2.2 Global High Potency APIs (HPAPI) Revenue Share by Manufacturers (2015-2020)
3.2.3 Global High Potency APIs (HPAPI) Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in High Potency APIs (HPAPI) as of 2019)
3.4 Global High Potency APIs (HPAPI) Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers High Potency APIs (HPAPI) Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into High Potency APIs (HPAPI) Market
3.7 Key Manufacturers High Potency APIs (HPAPI) Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global High Potency APIs (HPAPI) Historic Market Review by Type (2015-2020)
4.1.2 Global High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
4.1.3 Global High Potency APIs (HPAPI) Revenue Market Share by Type (2015-2020)
4.1.4 High Potency APIs (HPAPI) Price by Type (2015-2020)
4.1 Global High Potency APIs (HPAPI) Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global High Potency APIs (HPAPI) Sales Forecast by Type (2021-2026)
4.2.3 Global High Potency APIs (HPAPI) Revenue Forecast by Type (2021-2026)
4.2.4 High Potency APIs (HPAPI) Price Forecast by Type (2021-2026)
5 Global High Potency APIs (HPAPI) Market Size by Application
5.1 Global High Potency APIs (HPAPI) Historic Market Review by Application (2015-2020)
5.1.2 Global High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)
5.1.3 Global High Potency APIs (HPAPI) Revenue Market Share by Application (2015-2020)
5.1.4 High Potency APIs (HPAPI) Price by Application (2015-2020)
5.2 Global High Potency APIs (HPAPI) Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global High Potency APIs (HPAPI) Sales Forecast by Application (2021-2026)
5.2.3 Global High Potency APIs (HPAPI) Revenue Forecast by Application (2021-2026)
5.2.4 High Potency APIs (HPAPI) Price Forecast by Application (2021-2026)
6 North America
6.1 North America High Potency APIs (HPAPI) Breakdown Data by Company
6.2 North America High Potency APIs (HPAPI) Breakdown Data by Type
6.3 North America High Potency APIs (HPAPI) Breakdown Data by Application
6.4 North America High Potency APIs (HPAPI) Breakdown Data by Countries
6.4.1 North America High Potency APIs (HPAPI) Sales by Countries
6.4.2 North America High Potency APIs (HPAPI) Revenue by Countries
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe High Potency APIs (HPAPI) Breakdown Data by Company
7.2 Europe High Potency APIs (HPAPI) Breakdown Data by Type
7.3 Europe High Potency APIs (HPAPI) Breakdown Data by Application
7.4 Europe High Potency APIs (HPAPI) Breakdown Data by Countries
7.4.1 Europe High Potency APIs (HPAPI) Sales by Countries
7.4.2 Europe High Potency APIs (HPAPI) Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific High Potency APIs (HPAPI) Breakdown Data by Company
8.2 Asia Pacific High Potency APIs (HPAPI) Breakdown Data by Type
8.3 Asia Pacific High Potency APIs (HPAPI) Breakdown Data by Application
8.4 Asia Pacific High Potency APIs (HPAPI) Breakdown Data by Regions
8.4.1 Asia Pacific High Potency APIs (HPAPI) Sales by Regions
8.4.2 Asia Pacific High Potency APIs (HPAPI) Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America High Potency APIs (HPAPI) Breakdown Data by Company
9.2 Latin America High Potency APIs (HPAPI) Breakdown Data by Type
9.3 Latin America High Potency APIs (HPAPI) Breakdown Data by Application
9.4 Latin America High Potency APIs (HPAPI) Breakdown Data by Countries
9.4.1 Latin America High Potency APIs (HPAPI) Sales by Countries
9.4.2 Latin America High Potency APIs (HPAPI) Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa High Potency APIs (HPAPI) Breakdown Data by Type
10.2 Middle East and Africa High Potency APIs (HPAPI) Breakdown Data by Application
10.3 Middle East and Africa High Potency APIs (HPAPI) Breakdown Data by Countries
10.3.1 Middle East and Africa High Potency APIs (HPAPI) Sales by Countries
10.3.2 Middle East and Africa High Potency APIs (HPAPI) Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E
11 Company Profiles
11.1 Pfizer (US)
11.1.1 Pfizer (US) Corporation Information
11.1.2 Pfizer (US) Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Pfizer (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Pfizer (US) High Potency APIs (HPAPI) Products and Services
11.1.5 Pfizer (US) SWOT Analysis
11.1.6 Pfizer (US) Recent Developments
11.2 Novartis (Switzerland)
11.2.1 Novartis (Switzerland) Corporation Information
11.2.2 Novartis (Switzerland) Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Novartis (Switzerland) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Novartis (Switzerland) High Potency APIs (HPAPI) Products and Services
11.2.5 Novartis (Switzerland) SWOT Analysis
11.2.6 Novartis (Switzerland) Recent Developments
11.3 Sanofi (France)
11.3.1 Sanofi (France) Corporation Information
11.3.2 Sanofi (France) Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Sanofi (France) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Sanofi (France) High Potency APIs (HPAPI) Products and Services
11.3.5 Sanofi (France) SWOT Analysis
11.3.6 Sanofi (France) Recent Developments
11.4 Roche (Switzerland)
11.4.1 Roche (Switzerland) Corporation Information
11.4.2 Roche (Switzerland) Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Roche (Switzerland) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Roche (Switzerland) High Potency APIs (HPAPI) Products and Services
11.4.5 Roche (Switzerland) SWOT Analysis
11.4.6 Roche (Switzerland) Recent Developments
11.5 Eli Lilly and Company (US)
11.5.1 Eli Lilly and Company (US) Corporation Information
11.5.2 Eli Lilly and Company (US) Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Eli Lilly and Company (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Eli Lilly and Company (US) High Potency APIs (HPAPI) Products and Services
11.5.5 Eli Lilly and Company (US) SWOT Analysis
11.5.6 Eli Lilly and Company (US) Recent Developments
11.6 Merck (US)
11.6.1 Merck (US) Corporation Information
11.6.2 Merck (US) Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Merck (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Merck (US) High Potency APIs (HPAPI) Products and Services
11.6.5 Merck (US) SWOT Analysis
11.6.6 Merck (US) Recent Developments
11.7 AbbVie (US)
11.7.1 AbbVie (US) Corporation Information
11.7.2 AbbVie (US) Business Overview and Total Revenue (2019 VS 2018)
11.7.3 AbbVie (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 AbbVie (US) High Potency APIs (HPAPI) Products and Services
11.7.5 AbbVie (US) SWOT Analysis
11.7.6 AbbVie (US) Recent Developments
11.8 Boehringer Ingelheim (Germany)
11.8.1 Boehringer Ingelheim (Germany) Corporation Information
11.8.2 Boehringer Ingelheim (Germany) Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Products and Services
11.8.5 Boehringer Ingelheim (Germany) SWOT Analysis
11.8.6 Boehringer Ingelheim (Germany) Recent Developments
11.9 GlaxoSmithKline (UK)
11.9.1 GlaxoSmithKline (UK) Corporation Information
11.9.2 GlaxoSmithKline (UK) Business Overview and Total Revenue (2019 VS 2018)
11.9.3 GlaxoSmithKline (UK) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 GlaxoSmithKline (UK) High Potency APIs (HPAPI) Products and Services
11.9.5 GlaxoSmithKline (UK) SWOT Analysis
11.9.6 GlaxoSmithKline (UK) Recent Developments
11.10 RAG-Stiftung (Germany)
11.10.1 RAG-Stiftung (Germany) Corporation Information
11.10.2 RAG-Stiftung (Germany) Business Overview and Total Revenue (2019 VS 2018)
11.10.3 RAG-Stiftung (Germany) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 RAG-Stiftung (Germany) High Potency APIs (HPAPI) Products and Services
11.10.5 RAG-Stiftung (Germany) SWOT Analysis
11.10.6 RAG-Stiftung (Germany) Recent Developments
11.11 Bristol-Myers Squibb (US)
11.11.1 Bristol-Myers Squibb (US) Corporation Information
11.11.2 Bristol-Myers Squibb (US) Business Overview and Total Revenue (2019 VS 2018)
11.11.3 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.11.4 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Products and Services
11.11.5 Bristol-Myers Squibb (US) SWOT Analysis
11.11.6 Bristol-Myers Squibb (US) Recent Developments
11.12 Teva (Israel)
11.12.1 Teva (Israel) Corporation Information
11.12.2 Teva (Israel) Business Overview and Total Revenue (2019 VS 2018)
11.12.3 Teva (Israel) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.12.4 Teva (Israel) High Potency APIs (HPAPI) Products and Services
11.12.5 Teva (Israel) SWOT Analysis
11.12.6 Teva (Israel) Recent Developments
11.13 Mylan (US)
11.13.1 Mylan (US) Corporation Information
11.13.2 Mylan (US) Business Overview and Total Revenue (2019 VS 2018)
11.13.3 Mylan (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.13.4 Mylan (US) High Potency APIs (HPAPI) Products and Services
11.13.5 Mylan (US) SWOT Analysis
11.13.6 Mylan (US) Recent Developments
11.14 AstraZeneca (UK)
11.14.1 AstraZeneca (UK) Corporation Information
11.14.2 AstraZeneca (UK) Business Overview and Total Revenue (2019 VS 2018)
11.14.3 AstraZeneca (UK) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.14.4 AstraZeneca (UK) High Potency APIs (HPAPI) Products and Services
11.14.5 AstraZeneca (UK) SWOT Analysis
11.14.6 AstraZeneca (UK) Recent Developments
11.15 Lonza (Swiss)
11.15.1 Lonza (Swiss) Corporation Information
11.15.2 Lonza (Swiss) Business Overview and Total Revenue (2019 VS 2018)
11.15.3 Lonza (Swiss) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.15.4 Lonza (Swiss) High Potency APIs (HPAPI) Products and Services
11.15.5 Lonza (Swiss) SWOT Analysis
11.15.6 Lonza (Swiss) Recent Developments
11.16 Ash Stevens (US)
11.16.1 Ash Stevens (US) Corporation Information
11.16.2 Ash Stevens (US) Business Overview and Total Revenue (2019 VS 2018)
11.16.3 Ash Stevens (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.16.4 Ash Stevens (US) High Potency APIs (HPAPI) Products and Services
11.16.5 Ash Stevens (US) SWOT Analysis
11.16.6 Ash Stevens (US) Recent Developments
11.17 AMRI (US)
11.17.1 AMRI (US) Corporation Information
11.17.2 AMRI (US) Business Overview and Total Revenue (2019 VS 2018)
11.17.3 AMRI (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.17.4 AMRI (US) High Potency APIs (HPAPI) Products and Services
11.17.5 AMRI (US) SWOT Analysis
11.17.6 AMRI (US) Recent Developments
12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 High Potency APIs (HPAPI) Sales Channels
12.2.2 High Potency APIs (HPAPI) Distributors
12.3 High Potency APIs (HPAPI) Customers
13 Estimates and Projections by Regions (2021-2026)
13.1 Global High Potency APIs (HPAPI) Sales Forecast (2021-2026)
13.1.1 Global High Potency APIs (HPAPI) Sales Forecast by Regions (2021-2026)
13.1.2 Global High Potency APIs (HPAPI) Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America High Potency APIs (HPAPI) Sales Forecast (2021-2026)
13.2.2 North America High Potency APIs (HPAPI) Revenue Forecast (2021-2026)
13.2.3 North America High Potency APIs (HPAPI) Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe High Potency APIs (HPAPI) Sales Forecast (2021-2026)
13.3.2 Europe High Potency APIs (HPAPI) Revenue Forecast (2021-2026)
13.3.3 Europe High Potency APIs (HPAPI) Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific High Potency APIs (HPAPI) Sales Forecast (2021-2026)
13.4.2 Asia Pacific High Potency APIs (HPAPI) Revenue Forecast (2021-2026)
13.4.3 Asia Pacific High Potency APIs (HPAPI) Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America High Potency APIs (HPAPI) Sales Forecast (2021-2026)
13.5.2 Latin America High Potency APIs (HPAPI) Revenue Forecast (2021-2026)
13.5.3 Latin America High Potency APIs (HPAPI) Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa High Potency APIs (HPAPI) Sales Forecast (2021-2026)
13.6.2 Middle East and Africa High Potency APIs (HPAPI) Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa High Potency APIs (HPAPI) Size Forecast by County (2021-2026)
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
【掲載企業】
Pfizer (US)、Novartis (Switzerland)、Sanofi (France)、Roche (Switzerland)、Eli Lilly and Company (US)、Merck (US)、AbbVie (US)、Boehringer Ingelheim (Germany)、GlaxoSmithKline (UK)、RAG-Stiftung (Germany)、Bristol-Myers Squibb (US)、Teva (Israel)、Mylan (US)、AstraZeneca (UK)、Lonza (Swiss)、Ash Stevens (US)、AMRI (US)
【免責事項】
https://www.globalresearch.jp/disclaimer